Advair
Product Images NDC 68258-3031

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair (NDC 68258-3031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (0cb2779f C60a 485b 8fc4 A9c454dde244 01)

This figure includes three Kaplan-Meier cumulative incidence plots comparing asthma-related death rates over a treatment duration of 196 days for subjects receiving Salmeterol versus placebo. The top graph shows all subjects, the middle graph shows Caucasian subjects, and the bottom graph shows African American subjects. The number of subjects at risk at different time points is listed below each graph for both Salmeterol and placebo groups.*

FDA Label Image

Chemical Structure Fp (0cb2779f C60a 485b 8fc4 A9c454dde244 02)

Chemical structure diagram of ADVAIR DISKUS active ingredient, showing its molecular bonds and configuration in standard chemical notation.*

FDA Label Image

Chemical Structure Salmeterol (0cb2779f C60a 485b 8fc4 A9c454dde244 03)

Chemical structure diagram showing molecular formulas of the active ingredients in ADVAIR DISKUS. The diagram features two distinct chemical structures representing the components typically found in this medication.*

FDA Label Image

Figure 2 (0cb2779f C60a 485b 8fc4 A9c454dde244 04)

A line chart depicting % change in FEV1 over 12 weeks plus an endpoint for four treatment groups: ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph shows time (weeks) on the x-axis and % change in FEV1 on the y-axis, with ADVAIR DISKUS showing the highest increase throughout the study period.*

FDA Label Image

Figure 3 (0cb2779f C60a 485b 8fc4 A9c454dde244 05)

Line graph showing the percentage change in FEV1 over 12 hours for four treatment groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The graph tracks respiratory function changes from baseline on Day 1, with ADVAIR DISKUS demonstrating the highest percentage increase in FEV1.*

FDA Label Image

Figure 4 (0cb2779f C60a 485b 8fc4 A9c454dde244 06)

A line graph comparing percentage change in FEV1 relative to Day 1 baseline over 12 hours for ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph shows ADVAIR DISKUS with the highest increase and sustained effect compared to other treatments and placebo.*

FDA Label Image

Figure 5 (0cb2779f C60a 485b 8fc4 A9c454dde244 07)

A line graph showing percent change in FEV1 over 24 weeks for three groups: ADVAIR DISKUS 250/50 administered twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph tracks changes from baseline FEV1 values with group sample sizes indicated below the x-axis (weeks).*

FDA Label Image

Figure 6 (0cb2779f C60a 485b 8fc4 A9c454dde244 08)

This line chart depicts the percentage change in FEV1 over 24 weeks comparing ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo. The x-axis shows time from day 1 to week 24, and the y-axis shows percent change in FEV1. ADVAIR DISKUS demonstrates the highest improvement, fluticasone propionate intermediate, and placebo the least. Sample sizes at various time points are also listed.*

FDA Label Image

Mg Parts Illustration (0cb2779f C60a 485b 8fc4 A9c454dde244 09)

An instructional diagram of the ADVAIR DISKUS inhaler highlighting key components including the lever, mouthpiece, dose indicator, thumbgrip, and outer case. The device label shows the strength as 100/50 mcg of fluticasone propionate/salmeterol inhalation powder.*

FDA Label Image

Mg Figure 1 (0cb2779f C60a 485b 8fc4 A9c454dde244 10)

Close-up image of an ADVAIR DISKUS inhaler device showing part of its mouthpiece and a white label on the body. The device is designed for inhalation use, with visible ridges on the device cover. The label includes some text but is not fully legible in the image. The inhaler is associated with Dispensing Solutions Inc.*

FDA Label Image

Mg Figure 2 (0cb2779f C60a 485b 8fc4 A9c454dde244 11)

Instructional diagram showing a hand holding an ADVAIR DISKUS inhaler, demonstrating the motion to push the lever to prepare a dose. The illustration indicates the direction to push the lever using an arrow, highlighting proper device usage steps.*

FDA Label Image

Mg Figure 3 (0cb2779f C60a 485b 8fc4 A9c454dde244 12)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler, demonstrating how to operate the device by moving the lever to prepare a dose for inhalation. The label on the inhaler indicates the product name and dosage information.*

FDA Label Image

Mg Figure 4 (0cb2779f C60a 485b 8fc4 A9c454dde244 13)

An illustration of a person holding a circular inhaler device near their mouth. The person appears to be preparing to use the inhaler, demonstrating proper use technique for an inhaled medication device.*

FDA Label Image

Mg Figure 5 (0cb2779f C60a 485b 8fc4 A9c454dde244 14)

An illustration showing a person using an ADVAIR DISKUS inhaler device, placing it near their mouth, demonstrating the inhalation technique.*

FDA Label Image

Mg Figure 6 (0cb2779f C60a 485b 8fc4 A9c454dde244 15)

An instructional illustration showing how to hold and operate an ADVAIR DISKUS inhaler. Two hands hold the device, with an arrow indicating a rotating or sliding motion on the inhaler cover, demonstrating the step to prepare the device for use.*

FDA Label Image

Overwrap (Ndc 68258 3031 1)

Label for ADVAIR DISKUS 250/50 inhalation device by Dispensing Solutions Inc. Contains 1 Diskus with 1 foil strip of 60 blisters. Each blister delivers 250 mcg fluticasone propionate and 72.5 mcg salmeterol xinafoate (equivalent to 50 mcg salmeterol base). Includes usage instructions, lot number SAMPLE, expiration 00-00, and prescription number 20692636. Packaged by Dispensing Solutions, Santa Ana, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.